6Vehreschild JJ,Bohme A, Reichert D,et al. Treatment of invasive fungal infections in clinical practice:a multi-centre survey on customary dosing, treatment indications, efficacy and safety of voriconazole [ J ] : Int J Hematol,2008,87 : 126 - 131.
二级参考文献22
1[1]Potter M.Strategies for managing systemic fungal infection and the place of itraconazole.J Antimicrob Chemother,2005,56(Suppl 1):S49-S54
2[2]Bow EJ,et al.Antifungal prophylaxis for severely neutropenic chemotherapy recipients:a meta analysis of randomized-controlled clinical trials.Cancer,2002,94 (12):3230-3246
3[3]Marr KA,et al.Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients:long-term follow-up of a randomized,placebo-controlled trial.Blood,2000,96 (6):2055-2061
4[4]Winston DJ,et al.Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients.A multicenter,randomized trial.Ann Intern Med,2003,138 (9):705-713
5[5]Marr KA,et al.Itraconazole versus fluconazole for prevention offungal infections in patients receiving allogeneic stem cell transplants.Blood,2004,103 (4):1527-1533
6[6]Singh N.Changing spectrum of invasive candidiasis and its therapeutic implications.Clin Microbiol Infect,2001,7 (Suppl.2):S1 -S7
7[7]Maschmeyer G.The changing epidemiology of invasive fungal in fections:new threats.Int J Antimicrob Agents,2006,27 (Suppl 1):S3-S6
8[8]Boogaerts M,et al.Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy.A randomized,controlled trial.Ann Intern Med,2001,135 (6):412-422
9[9]Bow EJ.Of yeasts and hyphae:a hematologist's approach to antifungal therapy.Hematology Am Soc Hematol Educ Program,2006,361-367
10[10]Maertens J,et al.Galactomannan and computed tomographybased preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection:a prospective feasibility study.Clin Infect Dis,2005,41 (9):1242-1250
2Leroy O, Gangneux JP, Montravers P, et al. Epidemology, man- agement, and risk factors for death of invasive Candida infections- in critical care : a multicenter, prospective, observational study in- France(2005-2006). Crit Care Med,2009,37(5) :1612-1618.
3Pereda J,Noguera X,Boncompte E,et al.Efficacy offlutrimazole 1%powder in the treatment of tineapedis. Mycoses . 2003
